A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
A phase 3 trial of Giredestrant in advanced solid tumours, run by Genentech, Inc., now recruiting.
Overview
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) is a phase 3 interventional study registered as NCT07541079 by Genentech, Inc., with 300 participants planned, started 2026-08-25 and due to reach its primary completion in 2032-06-30. Interventions recorded: Giredestrant.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.